AOA Dx
Boulder, CO · Biotechnology, Other · 35 employees
AOA Dx is leading a revolutionary breakthrough in early-stage cancer detection for women, leveraging the transformative potential of AI and our proprietary biomarker technology. At the heart of this innovation is our GlycoLocate platform, a multi-omics approach powered by tumor marker gangliosides, lipids and proteins. This platform is setting a new gold standard in the quest for life-saving early
Funding history
- Venture - Series Unknown — $8.1M — Oct 2025
- Seed — $1.8M — Dec 2024
- Venture - Series Unknown — $23.6M — Jul 2023
- Venture - Series Unknown — $2.6M — Nov 2021
- Venture - Series Unknown — $2.5M — Jul 2021
Recent signals
- Oct 15, 2025: Raised $8.1M in Venture - Series Unknown
- Dec 19, 2024: Raised $1.8M in Seed
- Jul 26, 2023: Raised $23.6M in Venture - Series Unknown
- Nov 18, 2021: Raised $2.6M in Venture - Series Unknown
- Jul 07, 2021: Raised $2.5M in Venture - Series Unknown
See plans & pricing → Track AOA Dx’s funding, hiring, and signals — with verified contacts — on Fundz.